Melatonin and melatonin agonist for delirium in the elderly patients.

Abstract

The objective of this review is to summarize the available data on the use of melatonin and melatonin agonist for the prevention and management of delirium in the elderly patients from randomized controlled trials (RCTs). A systematic search of 5 major databases PubMed, MEDLINE, PsychINFO, Embase, and Cochrane Library was conducted. This search yielded a total of 2 RCTs for melatonin. One study compared melatonin to midazolam, clonidine, and control groups for the prevention and management of delirium in individuals who were pre- and posthip post-hip arthroplasty. The other study compared melatonin to placebo for the prevention of delirium in older adults admitted to an inpatient internal medicine service. Data from these 2 studies indicate that melatonin may have some benefit in the prevention and management of delirium in older adults. However, there is no evidence that melatonin reduces the severity of delirium or has any effect on behaviors or functions in these individuals. Melatonin was well tolerated in these 2 studies. The search for a melatonin agonist for delirium in the elderly patients yielded 1 study of ramelteon. In this study, ramelteon was found to be beneficial in preventing delirium in medically ill individuals when compared to placebo. Ramelteon was well tolerated in this study.

• Authors: Dwaipayan Chakraborti, Deena J Tampi, Rajesh R Tampi
• Journal: American journal of Alzheimer's disease and other dementias (Am J Alzheimers Dis Other Demen) Vol. 30 Issue 2 Pg. 119-29 (Mar 2015) ISSN: 1938-2731 [Electronic] United States
• PMID: 24946785 (Publication Type: Journal Article, Review)
• Copyright: © The Author(s) 2014.

Chemical References

• Indenes
• ramelteon
• Melatonin

Topics

• Aged
• Delirium (prevention & control, therapy)
• Humans
• Indenes (therapeutic use)
• Melatonin (agonists, therapeutic use)
• Randomized Controlled Trials as Topic